Shares of IRIDEX Co. (NASDAQ:IRIX) have been assigned an average broker rating score of 1.00 (Strong Buy) from the one brokers that provide coverage for the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a strong buy rating.
Analysts have set a 12 month consensus target price of $13.00 for the company and are anticipating that the company will post ($0.25) earnings per share for the current quarter, according to Zacks. Zacks has also assigned IRIDEX an industry rank of 179 out of 265 based on the ratings given to related companies.
Several research analysts recently commented on IRIX shares. Roth Capital reiterated a “buy” rating and issued a $13.00 price target on shares of IRIDEX in a research note on Friday, November 3rd. Zacks Investment Research upgraded IRIDEX from a “sell” rating to a “hold” rating in a research note on Wednesday, December 20th.
Several large investors have recently bought and sold shares of IRIX. Neuberger Berman Group LLC bought a new position in shares of IRIDEX during the third quarter valued at approximately $141,000. Susquehanna International Group LLP bought a new position in shares of IRIDEX during the second quarter valued at approximately $196,000. Ingalls & Snyder LLC bought a new position in shares of IRIDEX during the third quarter valued at approximately $234,000. Goldman Sachs Group Inc. bought a new position in IRIDEX in the 2nd quarter worth approximately $607,000. Finally, Osborne Partners Capital Management LLC bought a new position in IRIDEX in the 3rd quarter worth approximately $673,000. 49.31% of the stock is owned by institutional investors.
Shares of IRIDEX (NASDAQ IRIX) opened at $7.49 on Tuesday. IRIDEX has a 1 year low of $7.40 and a 1 year high of $16.37. The stock has a market capitalization of $86.39, a PE ratio of -4.38 and a beta of 1.31.
IRIDEX (NASDAQ:IRIX) last issued its earnings results on Thursday, November 2nd. The medical equipment provider reported ($0.27) earnings per share for the quarter. IRIDEX had a negative return on equity of 23.21% and a negative net margin of 42.22%. analysts anticipate that IRIDEX will post -0.91 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Zacks: IRIDEX Co. (IRIX) Receives Consensus Rating of “Strong Buy” from Brokerages” was first reported by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2018/01/23/zacks-iridex-co-irix-receives-consensus-rating-of-strong-buy-from-brokerages.html.
IRIDEX Corporation is a provider of therapeutic based laser consoles, delivery devices and consumable instrumentation used to treat sight-threatening eye diseases in ophthalmology. The Company operates through ophthalmology segment. Its ophthalmology products consist of laser consoles, delivery devices and consumable instrumentation, including laser probes, and are used in the treatment of serious eye diseases, including the over three causes of irreversible blindness, such as diabetic retinopathy, glaucoma and age-related macular degeneration (AMD).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for IRIDEX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IRIDEX and related companies with MarketBeat.com's FREE daily email newsletter.